1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Achiko AG
  6. News
  7. Summary
    ACHI   CH0522213468


Delayed Swiss Exchange  -  05/27 11:31:37 am EDT
0.1000 CHF   -1.96%
05/25Achiko Secures $1.3 Million Financing with Strategic Investors Buranto AG and Negma Group
05/25Achiko AG Appoints Derek Brand to Advisory Board
05/25Achiko AG Secures $1.3 Million Financing with Strategic Investors Buranto AG and Negma Group
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Achiko AG Strengthens Senior Team with Appointment of Head of Corporate Development

01/27/2022 | 07:31am EDT
  • Achiko AG appoints David Hodge to the role of Head of Corporate Development in Switzerland
  • David Hodge will oversee Corporate Affairs, and Strategic and Corporate Development
  • Board Director Christophe Laurent to retire at month end

ZURICH, Switzerland, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LRAchiko AG (OTCQB: ACHKF) (SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) is pleased to announce the appointment of strategic and corporate development executive David Hodge to the position of Head of Corporate Development and announces the retirement of Christophe Laurent as Board Director.  

Mr. Hodge brings over 30 years’ experience as a C-suite executive including Australia’s then largest private equity firm (SBC Capital Partners), global investment banking (UBS), global manufacturing (Amcor) and industrial services businesses (Worley), and technology software businesses, with a focus on shareholder value creation. His broad sector experience includes healthcare, manufacturing, technology, and banking and finance.

He has been a strategic and corporate development advisor to world leading companies on business transformation and strategic challenges in emerging and developed markets, with a focus on profitable strategic growth. Clients have included ADM, Allnex, Amcor, AMVIG, Bayer, BTG, Campbells, Cornelius, Countrywide, Graphic Packaging International, MedHealth, NCO, Neovia, Nexans, Nine, SATS, SGH, Smith Group, Sumitomo, TGI Fridays, West Pharmaceutical, and Worley.

Previously, Mr. Hodge led major capital raisings in Australia, Hong Kong, China, Southeast Asia, USA, and Europe. He has led global strategic projects on every major continent and implemented numerous M&A projects worldwide. Mr. Hodge has served as a Director and Chairman of public listed and private companies in Asia Pacific. He holds a Bachelor of Economics and Bachelor of Laws from Monash University in Australia.

Mr. Hodge is responsible for the development of Achiko’s corporate presence especially in Switzerland, including for all matters regarding the development of the Board, corporate finance, and investor relations in its transformation to a world class diagnostics company.

Mr. Hodge started his role as Head of Corporate Development on January 21, 2022.

As previously announced, Board Director Christophe Laurent will retire on January 31, 2022. The Company will appoint a replacement for Mr. Laurent on or before the Annual General Meeting.

“As the Company pursues CE Mark registration for our affordable, non-invasive Covid-19 rapid test AptameX™ in Q1 2022, we are excited to welcome Mr. Hodge to our senior team. His rich strategic and corporate development experience will bring a new dimension to Achiko as we prepare for commercialization beyond Indonesia,” said Achiko CEO Steven Goh. “In addition, the Board of Directors is grateful for the efforts of Mr. Laurent, and I would like to thank him personally as his broad contributions across the company helped grow Achiko to where we are today.”

Achiko AG (OTCQB: ACHKF; SIX: ACHI.SW; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and an application for CE Mark approval in Europe will be submitted in 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX™ and companion health apps via its digital mobile health technology division, Teman Sehat™. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Hong Kong, Jakarta, Seoul, and Singapore.

Media contacts:

Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

U.S. & Global
Jeanene Timberlake
E: jtimberlake@rooneypartners.com
T: +1 646 770 8858

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties, and other factors, which could cause the actual results, financial condition, performance, or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

All news about ACHIKO AG
05/25Achiko Secures $1.3 Million Financing with Strategic Investors Buranto AG and Negma Gro..
05/25Achiko AG Appoints Derek Brand to Advisory Board
05/25Achiko AG Secures $1.3 Million Financing with Strategic Investors Buranto AG and Negma ..
05/25Achiko AG Secures CHF 1.25 million Financing with Strategic Investors Buranto AG and N..
05/25Achiko AG announced that it expects to receive CHF 1.25 million in funding from Negma G..
05/19Achiko Preliminarily Expects FY21 Loss as Annual Report Delayed by Pandemic, Staffing
05/19Achiko AG Reports Key Unaudited Financial Results for the Year Ended December 31, 2021
05/19Achiko AG Reports Key Unaudited Financial Results for the Year Ended 31 December 2021
05/19Achiko AG Reports Key Unaudited Financial Results for the Year Ended 31 December 2021
05/17Achiko AG Obtains CE Mark for AptameX™ Covid-19 Rapid Test
More news
Analyst Recommendations on ACHIKO AG
More recommendations
Financials (USD)
Sales 2020 2,81 M - -
Net income 2020 -14,1 M - -
Net Debt 2020 1,57 M - -
P/E ratio 2020 -2,61x
Yield 2020 -
Capitalization 13,9 M 13,9 M -
EV / Sales 2019 -
EV / Sales 2020 14,0x
Nbr of Employees 29
Free-Float 63,9%
Duration : Period :
Achiko AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACHIKO AG
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Steven Goh Chief Executive Officer & Director
Morris S. Berrie President
Adam O’Keeffe Chief Financial Officer
Yao Bian Wu Chairman
Ann Chow Head-Investor Relations
Sector and Competitors
1st jan.Capi. (M$)
ACHIKO AG-42.53%14
INTUIT INC.-34.32%119 172
ADYEN N.V.-34.36%50 340
WORLDLINE-18.69%11 979
KAKAO PAY CORP.-40.40%10 967